Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

ClinicalTrials.gov ID: NCT01524783

Public ClinicalTrials.gov record NCT01524783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of carcinoid syndrome.

Study identification

NCT ID: NCT01524783
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 302 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 30, 2012 (Actual)
Primary completion: Nov 28, 2014 (Actual)
Completion: Aug 7, 2020 (Actual)
Last update posted: Aug 5, 2021

2012 – 2020

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California San Diego - Moores Cancer Center Regulatory	La Jolla	California	92093-0658	—
Scripps Clinic Regulatory	La Jolla	California	92121	—
Cedars Sinai Medical Center SC	Los Angeles	California	90048	—
University of Colorado Cancer Centre SC	Aurora	Colorado	80045	—
H Lee Moffitt Cancer Center and Research Institute HLM	Tampa	Florida	33612	—
University of Chicago UC SC	Chicago	Illinois	60637	—
Goshen Center for Cancer Care IU Health SC	Indianapolis	Indiana	46202	—
Dana Farber Cancer Institute SC	Boston	Massachusetts	02215	—
Memorial Sloan Kettering MSkCC SC	New York	New York	10017	—
Montefiore Medical Center MMC	The Bronx	New York	10467	—
Oregon Health and Science University OH&SU	Portland	Oregon	97239	—
Vanderbilt University Medical Center Vanderbilt Med Ctr	Nashville	Tennessee	37232	—
Texas Oncology P A Texas Oncology Amarillo	Dallas	Texas	75251	—
Texas Oncology P A TX Oncology Baylor	Dallas	Texas	75251	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
University of Texas MD Anderson Cancer Center UT MD Anderson Cancer Ctr	Houston	Texas	77030	—
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc	Madison	Wisconsin	53792-6164	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01524783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 5, 2021 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01524783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →